Refine by
Parkinsons Disease Articles & Analysis
113 news found
Bronchiectasis APIs for Respiratory Health In respiratory health, Protheragen-ING brings APIs like umeclidinium bromide and vilanterol trifenatate for bronchiectasis, a chronic disease in which bronchi are widened and mucus is not cleared, which results in infection. ...
Currently, Protheragen-ING provides products and services like API products, pharmaceutical excipients, veterinary products, chemical products, intermediates, active pharmaceutical ingredients services, drug formulation development, drug delivery system development, anti-tumor API, hypoglycemic API, API for parkinson's disease, natural extract, chemical contract ...
Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases. Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of life. Depression is commonly seen in neurodegenerative and neurodevelopmental diseases such as ...
Medical probiotic leader Bened Biomedical Co., Ltd., which develops and markets neuroactive probiotic products, announced a completed Series A round of fundraising, receiving more than $10 million of capital from two prominent investors, Trans-Pacific Technology Fund (TPTF) and JAFCO Asia. With strategic support from these venture capital partners, Bened expects to rapidly expand its ...
The companies will jointly develop the compounds for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications based on early-stage clinical studies, and consider exploring additional indications based on clinical outcomes. ...
BlueRock, a pioneer in stem cell engineered cell therapy, is advancing a growing pipeline of innovative therapies for treating patients with neurological, immunological, cardiovascular and ophthalmic diseases. Its most advanced program BRT-DA01 is being developed for the treatment of Parkinson’s disease, a progressive neurodegenerative ...
ByBayer AG
“We are excited to combine these unique platforms to develop next-generation genetic therapies with the potential to transform the lives of patients suffering from a wide range of debilitating genetic diseases.” In June 2022, ReCode announced the closing of a $200 million Series B extension financing round, co-led by Leaps by Bayer, the impact investment unit of ...
ByBayer AG
The PTR platform has the opportunity to be used for delivery of medications in other large markets, including anxiety (CTx-2103 in development), insomnia, depression, bipolar disorder, Parkinson’s disease, xerostomia (dry mouth), migraine, and hypothyroidism. ...
The technology is designed to advance treatments for neurodegenerative diseases, including therapies with complex molecules such as monoclonal antibodies and larger peptides, by allowing medication to cross the blood-brain barrier and access the most penetrable part of the blood-brain barrier at the top of the nasal cavity. Led by a team of experienced entrepreneurs with ...
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s Identified two lead cannabinoid analog compounds for in vivo studies NSERC grant funding supports InMed’s collaborative research projects with Dr. ...
Over the past 90 days, the Company has been focused on the optimization of its Rotigotine TDS formulation for the treatment of Parkinson’s disease, with multiple novel but related formulas under development. ...
Ariana Pharma, the leading Al-driven precision medicine company, has announced the first comprehensive blarcamesine pathway analysis impact using extensive data from the ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia (PDD) clinical study. Initial results were presented by Ariana Pharma at the Alzheimer’s Association International Conference ...
For more information, please visit http://www.flowonix.com About Cerebral Therapeutics Cerebral Therapeutics, LLC is a privately-held company founded with the goal of addressing the well-recognized limitations of existing treatments for uncontrolled neurological diseases. Cerebral Therapeutics is combining advanced micro-dosing technology with proprietary medications to ...
“Exosomes are a rapidly growing research area for biomarker discovery and the diagnosis and treatment of cancer and other diseases.” “There are different purposes for INOVIQ’s diagnostic products, from screening to detect disease earlier in asymptomatic people, through to diagnosis of disease and then monitoring patients ...
Infection: Needles come with risks, such as contamination and transmission of disease like hepatitis. However, per the CDC, infection is preventable using proper safe injection practices. ...
Future applications include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and hypertension. Synchron is headquartered in New York City, with R&D facilities in Melbourne, ...
Future applications include the potential to diagnose and treat conditions of the nervous system, including Parkinson’s disease, epilepsy, depression, and hypertension. Synchron is headquartered in New York City, with offices in Silicon Valley, California and R&D facilities in Melbourne, ...
INBRIJA® is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor such as phenelzine or tranylcypromine within the last two weeks. ...
“Esteve has a significant presence in Europe and an excellent track record of successfully commercializing neurological products there.” Parkinson’s disease is the second most common neurodegenerative disease in Germany. According to current population estimates, there are up to 400,000 people living with ...
Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, neuroscience, and device technology, Kurve Therapeutics is paving the way for revolutionary clinical success in treating complex CNS disorders including Alzheimer’s disease, cognitive aging, Lewy body dementia, and Parkinson’s ...